Research progress of radiopharmaceuticals targeting VEGF/VEGFR pathway
10.3760/cma.j.cn321828-20240826-00305
- VernacularTitle:靶向VEGF/VEGFR通路的放射性药物研究进展
- Author:
Yang PEI
1
;
Zhen CHENG
;
Ji HU
Author Information
1. 原子高科股份有限公司，北京 102413
- Publication Type:Journal Article
- Keywords:
Radiopharmaceuticals;
Vascular endothelial growth factors;
Receptors, vascular endothelial growth factor;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(8):508-512
- CountryChina
- Language:Chinese
-
Abstract:
The vascular endothelial growth factor (VEGF) family and the VEGF receptor (VEGFR) pathway play an important role in regulating tumor-induced angiogenesis. Consequently, inhibitors targeting the VEGF/VEGFR pathway have demonstrated potential as anti-angiogenic agents in cancer therapy. However, the clinical application of these inhibitors is currently limited by off-target toxicity and the heterogeneity of VEGF/VEGFR expression levels. Radiolabeled molecular probes targeting the VEGF/VEGFR pathway offer a non-invasive means to detect VEGF/VEGFR expression in tumors, aiding in therapeutic decision-making and efficacy evaluation of anti-angiogenic treatments. This article reviews the research progress of radiopharmaceuticals targeting the VEGF/VEGFR pathway in tumor diagnosis and treatment, with a focus on the role of structural modification methods in optimizing the performance of VEGF/VEGFR-targeting compounds, and provides an outlook on future research directions.
